1964. Package # 441 (Determining the risk of cancer development in a woman)

The package ‘Determining the risk of developing cancer in women’ is a complex of tumor markers to assess the risks of the most common oncological diseases in women: breast (CA 15-3), malignant neoplasms of the ovaries (two tumor markers CA 125 and HE 4), urinary tumors. uterus (tumor marker Cyfra CA 21-1 (cytokeratin fragment 19)), malignant tumors of the gastrointestinal tract (cancer-embryonic antigen (CEA, CEA)), lining the oral cavity of cancer of the mucous epithelium, cervix, head, anus or skin (squamous cell carcinoma antigen (SCC)).

These tests are recommended for women to comprehensively assess the risk of a wide range of cancers, especially if one of the relatives has or had cancer. In case of a change in the tumor markers, an additional examination is necessary, since an increase in indicators can be observed not only in the case of cancer, but also in inflammatory and benign processes.

It is desirable to supplement the package with an assessment of the risk of cervical cancer – package No. 129 ‘Cervical screening’, which includes optimal liquid cytology and detection of human papillomavirus, which is the cause of cervical cancer.

It is recommended to take this package to assess the risks of developing the most common forms of cancer in women.

• Venous blood

In order to exclude factors that may affect the test results, we recommend to follow the preparation rules: